Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Capoten exclusivity ends: Geneva generic shipments begin Nov. 10.

Executive Summary

CIBA/GENEVA BEGINS GENERIC CAPTOPRIL SHIPMENTS NOV. 10 following FDA approval of an ANDA for a version of Bristol-Myers Squibb's Capoten on Nov. 9. Geneva became the first outside company with a fully-approved ANDA for the ACE inhibitor when Bristol did not file suit against the company during the 45-day waiting period established under Waxman/Hatch for ANDAs with paragraph IV certifications.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel